No evidence of increased risk of acquired rifampin resistance
CMAJ
.
2019 Nov 25;191(47):E1314-E1315.
doi: 10.1503/cmaj.73353.
Authors
Dick Menzies
1
,
Victoria Cook
2
,
Richard Long
3
,
Rovina Ruslami
4
Affiliations
1
Professor, Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Que.
2
Clinical associate professor, Department of Medicine, University of British Columbia, Vancouver, BC.
3
Professor, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alta.
4
Professor, Department of Biomedical Sciences, Division of Pharmacology & Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, India.
PMID:
31767710
PMCID:
PMC6877362
DOI:
10.1503/cmaj.73353
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Isoniazid
Latent Tuberculosis*
Mycobacterium tuberculosis*
Rifampin
Substances
Isoniazid
Rifampin